Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

Published:2014-12-15 Issue:1 Volume:263 Page:68-89
ISSN:0105-2896
Container-title:Immunological Reviews
language:en
Short-container-title:Immunol Rev

Author:

Gill Saar¹,June Carl H.²

Affiliation:

1. Abramson Cancer Center, Division of Hematology/Oncology; Department of Medicine; University of Pennsylvania; Philadelphia PA USA

2. Abramson Cancer Center; Department of Pathology and Laboratory Medicine; University of Pennsylvania; Philadelphia PA USA

Funder

Office of Extramural Research, National Institutes of Health

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imr.12243/fullpdf

Reference175 articles.

1. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience;Lamers;J Clin Oncol,2006

2. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer;Kershaw;Clin Cancer Res,2006

3. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells;Till;Blood,2008

4. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans;Jensen;Biol Blood Marrow Transplant,2010

5. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N Engl J Med,2011

Cited by 283 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors;Cell Death & Disease;2024-05-24

2. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector;Journal of Microbiology;2024-05-03

3. Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications;Heliyon;2024-04

4. Discovering the strength of immunometabolism in cancer therapy: Employing metabolic pathways to enhance immune responses;Cell Biochemistry and Function;2024-01-28

5. The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer;Cell Transplantation;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3